Using an AI tool, researchers have analyzed brain images from 70-year-olds and estimated their brains' biological age. They found that factors detrimental to vascular health, such as inflammation and ...

Shares of Biogen Inc. BIIB sank 0.62% to $146.47 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.09% to 5,930.85 and the ...

In a report released today, Evan Seigerman from BMO Capital downgraded Biogen (BIIB – Research Report) to a Hold, with a price target of ...

The program, aimed at reducing how much Americans spend on prescription drugs, includes several precision medicines.

Biogen is reportedly in negotiations to lease up to 500,000 square feet as the first tenant at MIT’s redevelopment of the ...

Fintel reports that on December 20, 2024, BMO Capital downgraded their outlook for Biogen (NasdaqGS:BIIB) from Outperform to ...

BMO Capital downgraded Biogen (BIIB) to Market Perform from Outperform with a price target of $164, down from $230. Work is underway at Biogen, ...

Biogen is in advanced negotiations to consolidate its Kendall Square operations in MIT’s upcoming Volpe redevelopment, ...

The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.